间质性肺疾病中抗凝治疗与生存的关联:肺纤维化基金会患者登记分析
基于肺纤维化基金会患者登记中1911例间质性肺疾病患者的分析显示,174例(9.1%)接受抗凝治疗,其中93例(4.9%)用直接口服抗凝药(DOACs),81例(4.2%)用华法林。校正混杂因素后DOACs与死亡率升高无关联,华法林仍与死亡率升高相关。在IPF患者中,华法林与无移植生存降低相关,DOACs无此关联。
要点
- ILD患者中需要抗凝与死亡或移植风险升高相关,IPF和非IPF人群均如此
- 校正混杂后华法林仍与死亡率升高相关,DOACs则无此关联
- 华法林与DOACs两组间生存差异无统计学意义
核心结论
- 间质性肺疾病患者中需要抗凝治疗与死亡或移植风险增加相关,IPF和非IPF人群均存在此关联。
- 校正混杂因素后华法林仍与死亡率升高相关,而DOACs与死亡率升高无关联。
- 在IPF患者中,华法林与无移植生存降低相关,DOACs无此关联。
研究设计与样本
- 对肺纤维化基金会患者登记中全部患者进行回顾性分析,共纳入1911例间质性肺疾病患者。
- 患者分为三组:未抗凝组、DOACs组(93例,4.9%)和华法林组(81例,4.2%)。
- 采用Kaplan-Meier曲线和Cox比例风险模型分析生存。
主要发现
- 1911例中174例(9.1%)接受抗凝治疗。
- 校正混杂变量后,DOACs与死亡率升高无关联,华法林仍与死亡率升高相关。
- 华法林组与DOACs组间生存差异无统计学意义。
临床怎么用
- ILD患者启动抗凝时应评估死亡与移植风险,尤其需用华法林者。
- 需抗凝的ILD患者中,DOACs校正后未显示死亡率升高,华法林仍显示风险。
局限性
- 为登记数据分析,可能存在混杂与适应证偏倚。
- 抗凝组样本量较小(DOACs 93例,华法林81例)。
- 华法林与DOACs安全性差异需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aberrations in the coagulation system have been implicated in the pathogenesis of interstitial lung disease (ILD). Anticoagulants have been proposed as a potential therapy in ILD; however, a randomized controlled trial examining warfarin as a treatment for IPF was terminated early due to increased death rates. This has led some to speculate that warfarin specifically may be harmful in ILD, and use of direct oral anticoagulants (DOACs) could result in superior outcomes. RESEARCH QUESTION: The goal of this study was to delineate the relationship between anticoagulation and outcomes in patients with ILD through an analysis of the Pulmonary Fibrosis Foundation Patient Registry. STUDY DESIGN AND METHODS: An analysis of all patients in the Pulmonary Fibrosis Foundation Patient Registry was performed. Patients were stratified into three groups: no anticoagulation, DOAC use, or warfarin use. Survival was analyzed by using both Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Of 1,911 patients included in the analysis, 174 (9.1%) were given anticoagulants; 93 (4.9%) received DOACs, and 81 (4.2%) received warfarin. There was a twofold increased risk of death or transplant for patients receiving DOACS; for warfarin, the risk was over two and half times greater. DOACs were not associated with an increased risk of mortality following adjustment for confounding variables. However, even after adjustment, patients given the anticoagulant warfarin remained at increased risk of mortality. In patients with IPF, warfarin was associated with reduced transplant-free survival, but DOACs were not. There was no statistically significant difference in survival between those receiving warfarin and those receiving a DOAC. INTERPRETATION: The need for anticoagulation is associated with an increased risk for death or transplant in patients with ILD, in both the IPF and non-IPF population. Further research is required to determine if warfarin and DOACs present varying safety profiles in patients with ILD.
引用
- King CS, Freiheit E, Brown AW, et al. Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2020. PMID: 33075376. doi:10.1016/j.chest.2020.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。